Trabecular Quality and Cellular Characteristics of Normal, Diabetic, and Charcot Bone

Journal of Foot and Ankle Surgery

Volumn 50, Issue 6, 2011, Pages 648-653

  La Fontaine, Javier ^a   Shibuya, Naohiro ^a   Sampson, H Wayne ^a   Valderrama, Pilar ^b  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b Private Practice   (United States)

Author keywords

Bone mineral density; Diabetes mellitus; Histology; Neuroarthropathy; Trabeculae

Indexed keywords

ADULT; ARTICLE; BONE CELL; BONE STRUCTURE; BONE TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATORY INFILTRATE; MALE; NEUROPATHIC JOINT DISEASE; TRABECULAR BONE;

ADOLESCENT; ADULT; ARTHROPATHY, NEUROGENIC; BIOPSY, NEEDLE; BONE AND BONES; BONE DISEASES; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; METACARPAL BONES; REFERENCE VALUES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TARSAL BONES; YOUNG ADULT;

EID: 80054882326     PISSN: 10672516     EISSN: 15422224     Source Type: Journal    
DOI: 10.1053/j.jfas.2011.05.005     Document Type: Article

References (39)

1. Charcot JM. Sur quelques arthropathies qui paraissent dépendre d'une lésion du cerveau ou de la moëlle épinière. Archives de Physiologie Normale et Pathologique 1:161-78, 379-400, 1868.
2. Sinha S., Munichoodappa C.S., Kozak G.P. Neuro-arthropathy (Charcot joints) in diabetes mellitus (clinical study of 101 cases). Medicine (Baltimore) 1972, 51:191-210.
3. Armstrong D.G., Todd W.F., Lavery L.A., Harkless L.B., Bushman T.R. The natural history of acute Charcot's arthropathy in a diabetic foot specialty clinic. Diabet Med 1997, 14:357-363.
4. Edmonds M.E., Clarke M.B., Newton S., Barrett J., Watkins P.J. Increased uptake of bone radiopharmaceutical in diabetic neuropathy. Q J Med 1985, 57:843-855.
5. Delano P.J. Pathogenesis of Charcot's joint. AJR Am J Roentgenol 1946, 56:189-200.
6. Zaidi M. Neural surveillance of skeletal homeostasis. Cell Metab 2005, 1:219-221.
7. Irie K., Hara-Irie F., Ozawa H., Yajima T. Calcitonin gene-related peptide (CGRP)-containing nerve fibers in bone tissue and their involvement in bone remodeling. Microsc Res Tech 2002, 58:85-90.
8. Tuominen J.T., Impivaara O., Puukka P., Ronnemaa T. Bone mineral density in patients with type 1 and type 2 diabetes. Diabetes Care 1999, 22:1196-1200.
9. Geusens P.P., Landewe R.B., Garnero P., Chen D., Dunstan C.R., Lems W.F., Stinissen P., van der Heijde D.M., van der Linden S., Boers M. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum 2006, 54:1772-1777.
10. Granchi D., Pellacani A., Spina M., Cenni E., Savarino L.M., Baldini N., Giunti A. Serum levels of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand as markers of periprosthetic osteolysis. J Bone Joint Surg Am 2006, 88:1501-1509.
11. Vernal R., Chaparro A., Graumann R., Puente J., Valenzuela M.A., Gamonal J. Levels of cytokine receptor activator of nuclear factor kappa B ligand in gingival crevicular fluid in untreated chronic periodontitis patients. J Periodontol 2004, 75:1586-1591.
12. Melton L.J., Leibson C.L., Achenbach S.J., Therneau T.M., Khosla S. Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res 2008, 23:1334-1342.
13. Melton L.J., Riggs B.L., Leibson C.L., Achenbach S.J., Camp J.J., Bouxsein M.L., Atkinson E.J., Robb R.A., Khosla S. A bone structural basis for fracture risk in diabetes. J Clin Endocrinol Metab 2008, 93:4804-4809.
14. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR Bone histomorphometry: standardization of nomenclature, symbols, and units. J Bone Miner Res 1987, 2:595-610.
15. Pinzur M.S. Neutral ring fixation for high-risk nonplantigrade Charcot midfoot deformity. Foot Ankle Int 2007, 28:961-966.
16. Fabrin J., Larsen K., Holstein P.E. Arthrodesis with external fixation in the unstable or misaligned Charcot ankle in patients with diabetes mellitus. Int J Low Extrem Wounds 2007, 6:102-107.
17. Farber D.C., Juliano P.J., Cavanagh P.R., Ulbrecht J., Caputo G. Single stage correction with external fixation of the ulcerated foot in individuals with Charcot neuroarthropathy. Foot Ankle Int 2002, 23:130-134.
18. Schwartz A.V., Sellmeyer D.E., Ensrud K.E., Cauley J.A., Tabor H.K., Schreiner P.J., Jamal S.A., Black D.M., Cummings S.R. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 2001, 86:32-38.
19. Melton L.J., Leibson C.L., Achenbach S.J., Therneau T.M., Khosla S. Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res 2008, 23:1334-1342.
20. Melton L.J., Riggs B.L., Leibson C.L., Achenbach S.J., Camp J.J., Bouxsein M.L., Atkinson E.J., Robb R.A., Khosla S. A bone structural basis for fracture risk in diabetes. J Clin Endocrinol Metab 2008, 93:4804-4809.
21. Papa J., Myerson M., Girard P. Salvage, with arthrodesis, in intractable diabetic neuropathic arthropathy of the foot and ankle. J Bone Joint Surg Am 1993, 75:1056-1066.
22. Hanft J.R., Goggin J.P., Landsman A., Surprenant M. The role of combined magnetic field bone growth stimulation as an adjunct in the treatment of neuroarthropathy/Charcot joint: an expanded pilot study. J Foot Ankle Surg 1998, 37:510-515.
23. Grady J.F., O'Connor K.J., Axe T.M., Zager E.J., Dennis L.M., Brenner L.A. Use of electrostimulation in the treatment of diabetic neuroarthropathy. J Am Podiatr Med Assoc 2000, 90:287-294.
24. Pelton K., Hofer J.K., Thordarson D.B. Tibiotalocalcaneal arthrodesis using a dynamically locked retrograde intramedullary nail. Foot Ankle Int 2006, 27:759-763.
25. Eichenholtz S.N. Charcot Joints 1966, Charles C. Thomas, Springfield, IL.
26. Armstrong D.G., Lavery L.A. Monitoring healing of acute Charcot's arthropathy with infrared dermal thermometry. J Rehabil Res Dev 1997, 34:317-321.
27. Lips P., Courpron P., Meunier P.J. Mean wall thickness of trabecular bone packets in the human iliac crest: changes with age. Calcif Tissue Res 1978, 26:13-17.
28. Levy J.R., Murray E., Manolagas S., Olefsky J.M. Demonstration of insulin receptors and modulation of alkaline phosphatase activity by insulin in rat osteoblastic cells. Endocrinology 1986, 119:1786-1792.
29. Balint E., Szabo P., Marshall C.F., Sprague S.M. Glucose-induced inhibition of in vitro bone mineralization. Bone 2001, 28:21-28.
30. Machwate M., Zerath E., Holy X., Pastoureau P., Marie P.J. Insulin-like growth factor-I increases trabecular bone formation and osteoblastic cell proliferation in unloaded rats. Endocrinology 1994, 134:1031-1038.
31. La Fontaine J., Harkless L.B., Sylvia V.L., Carnes D., Heim-Hall J., Jude E. Levels of endothelial nitric oxide synthase and calcitonin gene-related peptide in the Charcot foot: a pilot study. J Foot Ankle Surg 2008, 47:424-429.
32. Petrova N.L., Foster A.V., Edmonds M.E. Calcaneal bone mineral density in patients with Charcot neuropathic osteoarthropathy: differences between type 1 and type 2 diabetes. Diabet Med 2005, 22:756-761.
33. Sinacore D.R., Hastings M.K., Bohnert K.L., Fielder F.A., Villareal D.T., Blair V.P., Johnson J.E. Inflammatory osteolysis in diabetic neuropathic (Charcot) arthropathies of the foot. Phys Ther 2008, 88:1399-1407.
34. Sinacore D.R., Bohnert K.L., Hastings M.K., Johnson J.E. Mid foot kinetics characterize structural polymorphism in diabetic foot disease. Clin Biomech (Bristol, Avon) 2008, 23:653-661.
35. Frykberg RG, Sanders LJ. The Charcot foot, In The High Risk Foot in Diabetes Mellitus, pp 325-35, edited by R Frykberg, Churchill Livingstone, New York, 1991.
36. Young M.J., Marshall A., Adams J.E., Selby P.L., Boulton A.J. Osteopenia, neurological dysfunction, and the development of Charcot neuroarthropathy. Diabetes Care 1995, 18:34-38.
37. Schini-Kerth V.B., Fisslthaler B., Busse R. CGRP enhances induction of NO synthase in vascular smooth muscle cells via a cAMP-dependent mechanism. Am J Physiol 1994, 267(6 Pt 2):H2483-H2490.
38. Naqvi A., Cuchacovich R., Saketkoo L., Espinoza L.R. Acute Charcot arthropathy successfully treated with pamidronate: long-term follow-up. Am J Med Sci 2008, 335:145-148.
39. Anderson J.J., Woelffer K.E., Holtzman J.J., Jacobs A.M. Bisphosphonates for the treatment of Charcot neuroarthropathy. J Foot Ankle Surg 2004, 43:285-289.